The authors evaluate the effect and safety of biosimilar trastuzumab MYL-1401O in human epidermal growth factor receptor 2 (HER2)–positive early-stage (neoadjuvant and adjuvant therapy ...

Researchers found no significant differences in safety outcomes between trastuzumab biosimilars and the originator product across subgroups. Trastuzumab biosimilars have similar safety profiles as ...

We also estimate total treatment costs of biologic and biosimilar forms of trastuzumab from 2005 to 2022 and describe changes in their market share. We find that the first biosimilar entrant's price ...

Number 5: Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained ...

These drugs are called biosimilars. They have “no clinically meaningful differences” in terms of safety, purity, or potency. Trastuzumab and hyaluronidase (Herceptin Hylecta) is another type ...

Using Medicare claims, we documented US prescribing patterns for originator biologic trastuzumab (Herceptin), a targeted cancer therapy, and five biosimilar entrants since 2019. The first ...

Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...

trastuzumab, July 2019; and pegfilgrastim, July 2018. “Late entrants” are product classes that had their first biosimilar/follow-on product enter the market in 2018 or 2019. a Biosimilar or ...

While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...

This week, CuraTeQ Biologics (a wholly owned step-down subsidiary of Aurobindo Pharma Limited) announced that its trastuzumab biosimilar, DAZUBLYS, has received a positive opinion from the ...

The FDA has approved trastuzumab-strf as a biosimilar to trastuzumab for the treatment of certain patients with HER2-overexpressing malignancies, according to a press release from the agent’s ...

biosimilar • Hercessi for Herceptin (trastuzumab) biosimilar • Opuviz, Yesafili, and Ahzantive for Eylea (aflibercept) biosimilar • Bkemv for Soliris (eculizumab) biosimilar • Nypozi for ...